Anhui Fengyuan Pharmaceutical Co., Ltd. (SHE:000153)
China · Delayed Price · Currency is CNY 6.65
+0.09 (1.37%)
Feb 4, 2026, 3:04 PM CST
SHE:000153 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,059 | 4,196 | 4,177 | 3,931 | 3,603 | 3,263 |
Other Revenue | 89.04 | 89.04 | 98.88 | 73.24 | 49.3 | 58.33 |
| 4,148 | 4,285 | 4,275 | 4,004 | 3,652 | 3,321 | |
Revenue Growth (YoY) | -3.81% | 0.21% | 6.78% | 9.63% | 9.97% | 2.57% |
Cost of Revenue | 3,410 | 3,357 | 3,185 | 2,885 | 2,572 | 2,175 |
Gross Profit | 738.75 | 927.3 | 1,091 | 1,119 | 1,081 | 1,146 |
Selling, General & Admin | 521.61 | 650.91 | 781.9 | 847.27 | 816.65 | 916.46 |
Research & Development | 66.94 | 63.13 | 77.02 | 65.47 | 76.02 | 75.47 |
Other Operating Expenses | 74.68 | 33.96 | 37.58 | 32.1 | 30.31 | 32.13 |
Operating Expenses | 671.32 | 755.39 | 897.19 | 949.35 | 924.51 | 1,023 |
Operating Income | 67.43 | 171.91 | 193.62 | 169.83 | 156.05 | 122.72 |
Interest Expense | -33.33 | -30.36 | -33.89 | -32.87 | -39.26 | -39.47 |
Interest & Investment Income | 10.86 | 11.4 | 14.05 | 9.1 | 4.27 | 22.31 |
Currency Exchange Gain (Loss) | 0.11 | 0.11 | 0.14 | 0.48 | -0.35 | -0.52 |
Other Non Operating Income (Expenses) | -5.92 | -3.29 | 2.44 | -2.23 | 0.8 | -4.41 |
EBT Excluding Unusual Items | 39.15 | 149.78 | 176.36 | 144.31 | 121.52 | 100.64 |
Impairment of Goodwill | - | - | - | - | -3.59 | - |
Gain (Loss) on Sale of Investments | 6.1 | -5.28 | -6.92 | 11.08 | 9.4 | -1.07 |
Gain (Loss) on Sale of Assets | -0.68 | -1.61 | 4.38 | -0.25 | -0.51 | -0.33 |
Asset Writedown | -2.09 | -0.01 | -0.28 | -0.01 | -4.98 | -2.56 |
Other Unusual Items | 94.3 | 65.84 | 41.35 | 47.16 | 38 | 41.44 |
Pretax Income | 136.79 | 208.72 | 214.89 | 202.29 | 159.83 | 138.11 |
Income Tax Expense | 26.01 | 51.07 | 57.6 | 51.35 | 41.98 | 36.02 |
Earnings From Continuing Operations | 110.77 | 157.65 | 157.3 | 150.94 | 117.86 | 102.1 |
Minority Interest in Earnings | 3.04 | 3.18 | 1.99 | 3.49 | 5.13 | 1.62 |
Net Income | 113.82 | 160.83 | 159.29 | 154.43 | 122.98 | 103.72 |
Net Income to Common | 113.82 | 160.83 | 159.29 | 154.43 | 122.98 | 103.72 |
Net Income Growth | -30.65% | 0.97% | 3.15% | 25.57% | 18.57% | 28.18% |
Shares Outstanding (Basic) | 465 | 465 | 465 | 444 | 437 | 437 |
Shares Outstanding (Diluted) | 465 | 465 | 465 | 444 | 437 | 437 |
Shares Change (YoY) | -0.07% | -0.05% | 4.71% | 1.59% | 0.03% | -0.17% |
EPS (Basic) | 0.24 | 0.35 | 0.34 | 0.35 | 0.28 | 0.24 |
EPS (Diluted) | 0.24 | 0.35 | 0.34 | 0.35 | 0.28 | 0.24 |
EPS Growth | -30.60% | 1.02% | -1.49% | 23.60% | 18.53% | 28.39% |
Free Cash Flow | -58.76 | -17.78 | 102.64 | 358.23 | 104.78 | 102.01 |
Free Cash Flow Per Share | -0.13 | -0.04 | 0.22 | 0.81 | 0.24 | 0.23 |
Dividend Per Share | 0.100 | 0.100 | 0.107 | 0.071 | 0.071 | - |
Dividend Growth | -6.63% | -6.63% | 50.00% | - | - | - |
Gross Margin | 17.81% | 21.64% | 25.51% | 27.95% | 29.59% | 34.50% |
Operating Margin | 1.63% | 4.01% | 4.53% | 4.24% | 4.27% | 3.69% |
Profit Margin | 2.74% | 3.75% | 3.73% | 3.86% | 3.37% | 3.12% |
Free Cash Flow Margin | -1.42% | -0.41% | 2.40% | 8.95% | 2.87% | 3.07% |
EBITDA | 167.44 | 272.3 | 294.51 | 263.38 | 241.66 | 193.57 |
EBITDA Margin | 4.04% | 6.35% | 6.89% | 6.58% | 6.62% | 5.83% |
D&A For EBITDA | 100.01 | 100.38 | 100.89 | 93.55 | 85.61 | 70.85 |
EBIT | 67.43 | 171.91 | 193.62 | 169.83 | 156.05 | 122.72 |
EBIT Margin | 1.63% | 4.01% | 4.53% | 4.24% | 4.27% | 3.69% |
Effective Tax Rate | 19.02% | 24.47% | 26.80% | 25.39% | 26.26% | 26.08% |
Revenue as Reported | 4,148 | 4,285 | 4,275 | 4,004 | 3,652 | 3,321 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.